14th Jun 2013 12:43
Tissue Regenix Group plc
Result of AGM
YORK, 14 June, 2013 - Tissue Regenix Group plc ("Tissue Regenix" or "the Group") (AIM:TRX), the regenerative medical devices company, hereby provides notification that, at the Group's AGM held earlier today, all resolutions were duly proposed to shareholders and passed.
For additional information please contact:
Tissue Regenix Group plc | +44 (0)1904 435 176 |
Antony Odell, Managing Director Ian Jefferson, Chief Financial Officer | |
Jefferies International Ltd. | +44 (0)20 7029 8000 |
Simon Hardy Harry Nicholas | |
Newgate Communications | +44 (0)20 7680 6550 |
Alistair Kellie Andrew Jones |
About Tissue Regenix
Tissue Regenix (AIM: TRX) is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the world.
Related Shares:
Tissue Regenix Group